青年急性脑梗塞或缺血性脑血管病静脉溶栓的安全性及疗效观察
|
摘要
目的探讨青年急性脑梗塞或缺血性脑血管病患者采取静脉溶栓治疗的安全性及其临床疗效。方法抽取本院2015年1月至2018年1月收治的青年脑梗塞或缺血性脑血管病患者60例作为研究对象,纳入对象临床资料完整,愿意配合研究,按照随机双盲法分为观察组与对照组,每组30例患者。对照组按照常规治疗措施处理,而观察组则加用静脉溶栓治疗。对两组患者治疗前与治疗后神经功能缺损评分、Bathel指数评分进行评价,记录并发症情况,实施组间统计学分析。结果两组患者治疗前神经功能缺损评分、Bathel指数评分差异无统计学意义,治疗后观察组均明显优于对照组,差异有统计学意义(P<0.05);观察组患者并发症发生率为10.00%,显著低于对照组30.00%,差异有统计学意义(P<0.05)。结论青年急性脑梗塞或缺血性脑血管病静脉溶栓治疗不仅可以更好地改善患者的神经功能缺损症状,提高日常那个生活能力,且安全性高,值得借鉴。
Objective To investigate the safety and clinical efficacy of intravenous thrombolysis in young patients with acute cerebral infarction or ischemic cerebrovascular disease. Methods 60 cases of young patients with cerebral infarction or ischemic cerebrovascular disease admitted to our hospital from January 2015 to January 2018 were selected as research objects.The clinical data of the subjects included in the study were complete. They were willing to cooperate with the study and were divided according to a randomized, double-blind method. Observation group and control group, 30 patients in each group. The control group was treated according to conventional treatment measures, while the observation group was treated with intravenous thrombolysis. Neurologic impairment scores and Bathel index scores were evaluated before and after treatment in both groups of patients. Complications were recorded and statistical analysis was performed between groups. Results There was no significant difference between the two groups in neurological defects score and Bathel index score before treatment, and the observation group was significantly superior to the control group after treatment, with statistically significant differences(P<0.05). The incidence of complications in the observation group was 10.00%, which was significantly lower than that in the control group(30.00%), and the difference was statistically significant(P<0.05). Conclusion Intravenous thrombolytic therapy for young patients with acute cerebral infarction or ischemic cerebrovascular disease can not only better improve the symptoms of neurological deficits in patients, but also increase the daily life ability and safety, and it is worth learning from.
Objective To investigate the safety and clinical efficacy of intravenous thrombolysis in young patients with acute cerebral infarction or ischemic cerebrovascular disease. Methods 60 cases of young patients with cerebral infarction or ischemic cerebrovascular disease admitted to our hospital from January 2015 to January 2018 were selected as research objects.The clinical data of the subjects included in the study were complete. They were willing to cooperate with the study and were divided according to a randomized, double-blind method. Observation group and control group, 30 patients in each group. The control group was treated according to conventional treatment measures, while the observation group was treated with intravenous thrombolysis. Neurologic impairment scores and Bathel index scores were evaluated before and after treatment in both groups of patients. Complications were recorded and statistical analysis was performed between groups. Results There was no significant difference between the two groups in neurological defects score and Bathel index score before treatment, and the observation group was significantly superior to the control group after treatment, with statistically significant differences(P<0.05). The incidence of complications in the observation group was 10.00%, which was significantly lower than that in the control group(30.00%), and the difference was statistically significant(P<0.05). Conclusion Intravenous thrombolytic therapy for young patients with acute cerebral infarction or ischemic cerebrovascular disease can not only better improve the symptoms of neurological deficits in patients, but also increase the daily life ability and safety, and it is worth learning from.
引文
[1]宋亚彬.青年急性脑梗塞药物联合介入治疗[J].现代养生,2017,15(8):88.
[2]田佳楠,杨春晓.青年脑梗塞脑动脉狭窄危险因素的分析[J].哈尔滨医科大学学报,2016,50(4):357-361,376.
[3]鄢金枝,李彩琴.研究青年脑梗塞临床特点与发病原因[J].中国保健营养,2017,27(3):3.
[4]郑小军,刘娟,肖飞,等.青年脑梗死120例危险因素及病因亚型临床分析[J].陕西医学杂志,2016,45(11):1526-1527.
[5]王凯,荣良群,魏秀娥,等.青年轻型急性缺血性卒中患者静脉溶栓治疗转归的预测因素[J].国际脑血管病杂志,2015,19(8):584-587.
[6]何炳接,陈丹霞,陈云玉,等.缺血性院内卒中患者的溶栓疗效分析[J].中国神经精神疾病杂志,2017,43(1):4-7.
[7]刘艳全.急性缺血性脑血管病动脉溶栓与静脉溶栓治疗120例临床分析[J].中国保健营养,2013,19(9):733.
[8]黄银辉,林友榆,陈振杰,等.rt-PA与尿激酶溶栓治疗急性脑梗塞115例疗效比较[J].海南医学,2013,24(20):2979-2982.
[9]刘玲,刘琦,李红利,等.急性脑梗塞动脉内溶栓治疗时间及梗塞部位等因素对疗效的影响[J].西部医学,2014,26(6):765-767.
[10]李庆安,方明.尿激酶动脉溶栓与静脉溶栓治疗急性脑梗塞临床疗效比较[J].湖北医药学院学报,2011,30(1):47-49.
[11]许玫.对比rt-PA与尿激酶溶栓在急性脑梗塞患者治疗中的临床效果[J].中国卫生标准管理,2015,16(22):128-129.
[12]曹红梅,康小燕.阿替普酶溶栓在急性脑梗塞治疗中的应用及体会[J].北方药学,2014,22(12):59.
[2]田佳楠,杨春晓.青年脑梗塞脑动脉狭窄危险因素的分析[J].哈尔滨医科大学学报,2016,50(4):357-361,376.
[3]鄢金枝,李彩琴.研究青年脑梗塞临床特点与发病原因[J].中国保健营养,2017,27(3):3.
[4]郑小军,刘娟,肖飞,等.青年脑梗死120例危险因素及病因亚型临床分析[J].陕西医学杂志,2016,45(11):1526-1527.
[5]王凯,荣良群,魏秀娥,等.青年轻型急性缺血性卒中患者静脉溶栓治疗转归的预测因素[J].国际脑血管病杂志,2015,19(8):584-587.
[6]何炳接,陈丹霞,陈云玉,等.缺血性院内卒中患者的溶栓疗效分析[J].中国神经精神疾病杂志,2017,43(1):4-7.
[7]刘艳全.急性缺血性脑血管病动脉溶栓与静脉溶栓治疗120例临床分析[J].中国保健营养,2013,19(9):733.
[8]黄银辉,林友榆,陈振杰,等.rt-PA与尿激酶溶栓治疗急性脑梗塞115例疗效比较[J].海南医学,2013,24(20):2979-2982.
[9]刘玲,刘琦,李红利,等.急性脑梗塞动脉内溶栓治疗时间及梗塞部位等因素对疗效的影响[J].西部医学,2014,26(6):765-767.
[10]李庆安,方明.尿激酶动脉溶栓与静脉溶栓治疗急性脑梗塞临床疗效比较[J].湖北医药学院学报,2011,30(1):47-49.
[11]许玫.对比rt-PA与尿激酶溶栓在急性脑梗塞患者治疗中的临床效果[J].中国卫生标准管理,2015,16(22):128-129.
[12]曹红梅,康小燕.阿替普酶溶栓在急性脑梗塞治疗中的应用及体会[J].北方药学,2014,22(12):59.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |